Zenas BioPharma Faces Investor Suit Over Post-IPO Plunge

By Sydney Price · April 17, 2025, 4:08 PM EDT

Autoimmune disease therapeutics company Zenas BioPharma Inc. was hit with a proposed shareholder class action alleging that its registration statement for its September 2024 initial public offering overstated the amount of...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Buathongsri v. Zenas BioPharma, Inc. et al

Case Number

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

April 16, 2025

Recent Articles By Sydney

April 16, 2025
DexCom Execs Sued For Allegedly Misleading Growth Claims
April 11, 2025
Dentsply Brass Face Investor Suit Over Alleged Dental Injuries
March 19, 2025
Sotera Beats Shareholder Suit Over Sterigenics Emissions
March 12, 2025
Caribou Biosciences Brass Face Investor's Clinical Trials Suit
February 10, 2025
Pharma Co. Misled Investors On Depression Drug, Suit Says
January 22, 2025
Pharma Co. Says Ex-CEO's Alleged Misconduct Is Not Fraud
January 08, 2025
Biotech Co.'s Facility Failures Lost Investors Money, Suit Says
January 02, 2025
Edwards Brass Face Investor Suit Over Heart Valve Sales
December 02, 2024
Investor Alleges Medical Device Co. Misled On FDA Clearance
November 21, 2024
SEC Denied Civil Penalties Over Pot Pill Exec's 'Inexperience'